Oppenheimer lifts target for Pulse Biosciences stock to USD 60.00
Published on 10/15/2026 at 20:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst targets reset valuation
- Oppenheimer raised its Pulse Biosciences target to USD 60.00 on October 13, 2026.
- Second-quarter revenue was USD 434,000, while net loss reached USD 24.66 million.
- Pulse Biosciences stock costs EUR 39.50 at Lang & Schwarz on October 15, 2026 at 8:13 p.m. CEST.
- Pulse Biosciences expects its next earnings report on November 15, 2026, with market capitalization at USD 3.2 billion.
Pulse Biosciences stock (ISIN US74587B1017) is being reassessed after Oppenheimer lifted its target from USD 35.00 to USD 60.00 on October 13, 2026. Markets Insider reported that the firm kept its Outperform rating. Pulse Biosciences stock was trading at EUR 39.50 at Lang & Schwarz on October 15, 2026 at 8:13 p.m. CEST.
Mizuho sets a second target
The analyst reset was part of a wider reassessment of medical-device companies. Mizuho raised its Pulse Biosciences target from USD 45.00 to USD 55.00 on October 13, 2026 and retained an Outperform rating, according to Markets Insider. The report cited procedure-volume headwinds linked to changes involving the Affordable Care Act and Medicaid.
Price position and range
On Nasdaq, Pulse Biosciences was at USD 44.22 at 2:21 p.m. ET on October 15, 2026. That placed the stock 24.92 percent below its USD 58.90 52-week high and 252.07 percent above its USD 12.56 low. Trading volume was 211,557 shares against an average of 515,700 shares.
CNN identifies Pulse Biosciences as a Nasdaq-listed health technology company in medical specialties. Its second-quarter 2026 revenue was USD 434,000, up from USD 86,000 a year earlier, while net loss was USD 24.66 million and adjusted earnings per share were not provided in the source's summary.
Valuation and next date
Market capitalization stood at USD 3.2 billion, and the reported price-to-earnings ratio was minus 37.80. The same CNN market page lists November 15, 2026 as the next earnings date. No dividend yield was listed.
Comparison with peers
Pulse Biosciences (Nasdaq, USD): P/E minus 37.80, market capitalization USD 3.2 billion
Edwards Lifesciences (NYSE, USD): plus 0.21 percent, P/E 49.80, market capitalization USD 49.9 billion
Intuitive Surgical (Nasdaq, USD): plus 1.65 percent, P/E 48.63, market capitalization USD 150.9 billion
What the targets mean
The target revisions put analyst assumptions well above the latest Nasdaq price, but they do not change the company's reported earnings base. For investors, the next earnings date and the path from USD 434,000 in quarterly revenue matter more than the target spread alone.
Trading levels for investors
The Nasdaq quotation at USD 44.22 and the EUR 39.50 Lang & Schwarz indication describe different venues and currencies. The US quotation remains below the high of USD 58.90, while the European indication provides the evening trading level for German investors.
The further course of trading is shown by the continuously updated real-time quote of Pulse Biosciences stock.
Pulse Biosciences market data
- Company: Pulse Biosciences, Inc.
- ISIN: US74587B1017
- Ticker: PLSE
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 8:13 p.m. CEST): EUR 39.50
- Market capitalization: USD 3.2 billion (as of October 15, 2026)
- 52-week range: USD 12.56-58.90 (as of October 15, 2026)
- Sector / Industry: Health Technology / Medical Specialties
- Next earnings date: November 15, 2026
Market context: Market report S&P 500.
